Home Corrigendum to: Pediatric reference intervals for 29 Ortho VITROS 5600 immunoassays using the CALIPER cohort of healthy children and adolescents
Article Publicly Available

Corrigendum to: Pediatric reference intervals for 29 Ortho VITROS 5600 immunoassays using the CALIPER cohort of healthy children and adolescents

This erratum corrects the original online version which can be found here: https://doi.org/10.1515/cclm-2017-0349
  • Victoria Higgins , Angela W.S. Fung , Man Khun Chan , Joseph Macri and Khosrow Adeli EMAIL logo
Published/Copyright: February 12, 2020
Download Article (PDF)
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 58 Issue 4

Corrigendum to: Higgins V, Fung AWS, Chan MK, Macri J, Adeli K. Pediatric reference intervals for 29 Ortho VITROS 5600 immunoassays using the CALIPER cohort of healthy children and adolescents. Clinical Chemistry and Laboratory Medicine 2018; volume 56, Issue 2, pp. 327–340. (DOI: https://doi.org/10.1515/cclm-2017-0349).

  1. Table 1 (SI units) in the original article contains incorrect values for the progesterone reference interval for males aged 15 to <19 years. Corrected progesterone reference intervals are provided below in the corrected Table 1 (SI Units).

  2. Supplementary Table 2 (CON units) in the original article therefore also contains incorrect values for the progesterone reference interval for males aged 15 to <19 years. Additionally, the upper progesterone reference limit for 11 to <15 years, the female progesterone 15 to <19 years sample size, the TSH reference interval for 0 to <1 week, and the iPTH reference intervals contained errors. Corrected reference intervals are provided below in the corrected Supplementary Table 2 (CON units).

  3. While labeled as μg/L, the y-axis values for Troponin I in Figure 7A were displayed as ng/L. The correct y-axis is shown in the corrected Figure 7A below:

 

Corrected Table 1 (SI units).

Analyte Female reference intervals
 Male reference intervals
Age Lower limit Upper limit n Lower 90% confidence interval Upper 90% confidence interval Age Lower limit Upper limit n Lower 90% confidence interval Upper 90% confidence interval
Progesterone, nmol/L 0 to <2 weeks 7.9 >178 60 (2.5, 15) NA 0 to <2 weeks 7.9 >178 60 (2.5, 15) NA
2 weeks to –<11 years 0.49 12 312 (0.47, 0.57) (6.6, 17) 2 weeks to <11 years 0.49 12 312 (0.47, 0.57) (6.6, 17)
11 to <15 years 1.1 13 138 (1.0, 1.5) (7.8, 15) 11 to <15 years 1.1 13 138 (1.0, 1.5) (7.8, 15)
15 to <19 years 2.3 31.0 79 (2.2, 2.5) (12, 33) 15 to <19 years 2.8 9.1 79 (2.5, 3.0) (8.4, 9.8)
 

Corrected Supplementary Table 2 (CON units).

Analyte Female reference intervals
 Male reference intervals
Age Lower limit Upper limit n Lower 90% confidence interval Upper 90% confidence interval Age Lower limit Upper limit n Lower 90% confidence interval Upper 90% confidence interval
Progesterone, nmol/L 0 to <2 weeks 2.50 >56 60 (0.78, 4.83) NA 0 to <2 weeks 2.50 >56 60 (0.78, 4.80) NA
2 weeks to <11 years 0.15 3.8 312 (0.15, 0.18) (2.1, 5.4) 2 weeks to <11 years 0.15 3.8 312 (0.15, 0.18) (2.1, 5.4)
11 to <15 years 0.35 4.09 138 (0.32, 0.48) (2.5, 4.6) 11 to <15 years 0.35 4.09 138 (0.32, 0.48) (2.5, 4.6)
15 to <19 years 0.73 9.8 79 (0.69, 0.79) (8.1, 12) 15 to <19 years 0.88 2.9 79 (0.79, 0.94) (2.6, 3.1)
iPTH, pg/mL 0 to <2 weeks 5.38 108 45 (4.43, 7.45) (87.7, 124) 0 to <2 weeks 5.38 108 45 (4.43, 7.45) (87.7, 124)
2 weeks to <9 years 11.6 67.4 203 (10.4, 13.5) (60.7, 75.1) 2 weeks to <9 years 11.6 67.4 203 (10.4, 13.5) (60.7, 75.1)
9 to <15 years 17.9 122 269 (16.2, 18.3) (95.2, 131) 9 to <15 years 17.9 122 269 (16.2, 18.3) (95.2, 131)
15 to <19 years 13.6 62.9 84 (12.3, 15.7) (53.2, 70.6) 15 to <19 yrs 15.7 79.3 82 (14.3, 16.7) (71.7, 86.6)
TSH, μIU/mL 0 to <1 week 0.71 31.5 51 (0.31, 1.40) (25.9, 37.5) 0 to <1 week 0.71 31.5 51 (0.31, 1.40) (25.9, 37.5)
1 week to <19 years 0.86 5.70 600 (0.77, 0.94) (5.37, 6.28) 1 week to <19 years 0.86 5.70 600 (0.77, 0.94) (5.37, 6.28)
Figure 7A.  
Figure 7A.

 

Published Online: 2020-02-12
Published in Print: 2020-03-26

©2020 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. New insights on the analytical performances for detecting and quantifying monoclonal proteins
  4. Reviews
  5. Vitamin C measurement in critical illness: challenges, methodologies and quality improvements
  6. Early predictors of perinatal brain damage: the role of neurobiomarkers
  7. Opinion Paper – Point
  8. Mixing studies for lupus anticoagulant: mostly yes, sometimes no
  9. Opinion Paper – Counterpoint
  10. Mixing studies for lupus anticoagulant: mostly no, sometimes yes
  11. EFLM Consensus Paper
  12. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM
  13. Guidelines and Recommendations
  14. PREDICT: a checklist for preventing preanalytical diagnostic errors in clinical trials
  15. Genetics and Molecular Diagnostics
  16. Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction
  17. General Clinical Chemistry and Laboratory Medicine
  18. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis
  19. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins
  20. Use of clinical data and acceleration profiles to validate pneumatic transportation systems
  21. National survey on delta checks in clinical laboratories in China
  22. Assessment of the glomerular filtration rate (GFR) in kidney transplant recipients using Bayesian estimation of the iohexol clearance
  23. Performance of Afinion HbA1c measurements in general practice as judged by external quality assurance data
  24. Renal tubular epithelial cells add value in the diagnosis of upper urinary tract pathology
  25. Reference Values and Biological Variations
  26. Influence of ethnicity on biochemical markers of health and disease in the CALIPER cohort of healthy children and adolescents
  27. Cardiovascular Diseases
  28. Clinical evaluation of capillary B-type natriuretic peptide testing
  29. Infectious Diseases
  30. Thrombo-inflammatory prognostic score improves qSOFA for risk stratification in patients with sepsis: a retrospective cohort study
  31. Corrigendum
  32. Corrigendum to: Pediatric reference intervals for 29 Ortho VITROS 5600 immunoassays using the CALIPER cohort of healthy children and adolescents
  33. Letters to the Editor
  34. Potential risks in fecal microbiota transplantation
  35. Macro-aspartate aminotransferase syndrome: a case report
  36. Factitious severe acidosis in a patient, preanalytical considerations and prevention
  37. Methods for quick, accurate and cost-effective determination of the type 1 diabetes genetic risk score (T1D-GRS)
  38. Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: two case reports
  39. Serum immunoglobulin-A (IgA) concentrations in a general adult population: association with demographics and prevalence of selective IgA deficiency
  40. Evaluation of PFA-100 closure times in cord blood samples of healthy term and preterm neonates
  41. Disagreement between direct and indirect potentiometric Na+ determination in infancy and childhood
  42. Carryover issues with UF-5000 urine flow cytometry – how did we miss it?
https://doi.org/10.1515/cclm-2020-0041

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. New insights on the analytical performances for detecting and quantifying monoclonal proteins
  4. Reviews
  5. Vitamin C measurement in critical illness: challenges, methodologies and quality improvements
  6. Early predictors of perinatal brain damage: the role of neurobiomarkers
  7. Opinion Paper – Point
  8. Mixing studies for lupus anticoagulant: mostly yes, sometimes no
  9. Opinion Paper – Counterpoint
  10. Mixing studies for lupus anticoagulant: mostly no, sometimes yes
  11. EFLM Consensus Paper
  12. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM
  13. Guidelines and Recommendations
  14. PREDICT: a checklist for preventing preanalytical diagnostic errors in clinical trials
  15. Genetics and Molecular Diagnostics
  16. Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction
  17. General Clinical Chemistry and Laboratory Medicine
  18. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis
  19. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins
  20. Use of clinical data and acceleration profiles to validate pneumatic transportation systems
  21. National survey on delta checks in clinical laboratories in China
  22. Assessment of the glomerular filtration rate (GFR) in kidney transplant recipients using Bayesian estimation of the iohexol clearance
  23. Performance of Afinion HbA1c measurements in general practice as judged by external quality assurance data
  24. Renal tubular epithelial cells add value in the diagnosis of upper urinary tract pathology
  25. Reference Values and Biological Variations
  26. Influence of ethnicity on biochemical markers of health and disease in the CALIPER cohort of healthy children and adolescents
  27. Cardiovascular Diseases
  28. Clinical evaluation of capillary B-type natriuretic peptide testing
  29. Infectious Diseases
  30. Thrombo-inflammatory prognostic score improves qSOFA for risk stratification in patients with sepsis: a retrospective cohort study
  31. Corrigendum
  32. Corrigendum to: Pediatric reference intervals for 29 Ortho VITROS 5600 immunoassays using the CALIPER cohort of healthy children and adolescents
  33. Letters to the Editor
  34. Potential risks in fecal microbiota transplantation
  35. Macro-aspartate aminotransferase syndrome: a case report
  36. Factitious severe acidosis in a patient, preanalytical considerations and prevention
  37. Methods for quick, accurate and cost-effective determination of the type 1 diabetes genetic risk score (T1D-GRS)
  38. Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: two case reports
  39. Serum immunoglobulin-A (IgA) concentrations in a general adult population: association with demographics and prevalence of selective IgA deficiency
  40. Evaluation of PFA-100 closure times in cord blood samples of healthy term and preterm neonates
  41. Disagreement between direct and indirect potentiometric Na+ determination in infancy and childhood
  42. Carryover issues with UF-5000 urine flow cytometry – how did we miss it?
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 11.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2020-0041/html
Scroll to top button